Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing.
apoptosis
drug-resistant breast cancer
dual sensitization anti-resistant nanoparticles
photodynamic therapy
synergistic effect
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
09
2022
accepted:
08
12
2022
entrez:
17
2
2023
pubmed:
18
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
Current chemotherapy fails to offer a desirable efficacy in clinical treatment against breast cancer due to the extensive multi-drug resistance. In this study, we developed dual sensitization anti-resistant nanoparticles to treat refractory breast cancer, aiming to benefit from photodynamic therapy and chemotherapy. Hyaluronic acid (HA) derivative and photosensitizer chlorin e6 (Ce6) derivative were synthesized and confirmed by mass spectrometry. These derivatives and the chemotherapy agent paclitaxel were incorporated into nanoparticles by an emulsion-solvent evaporation method. The prepared nanoparticles were characterized by dynamic laser scattering, atomic force microscopy, and high performance liquid chromatography (HPLC). The efficacy and mechanisms of the nanoparticles, both in vitro and in vivo, were investigated by flow cytometry, confocal/fluorescence microscopy, and a high-content screening system. The prepared dual sensitization anti-resistant nanoparticles were round with a diameter of ~ 100 nm, exhibiting high encapsulation efficiency for the anticancer agent paclitaxel. The nanoparticles demonstrated a robust inhibitory effect against drug-resistant breast cancer cells by enhanced uptake, synergistic effect of photodynamic therapy and chemotherapy, and apoptosis-inducing via multiple pathways. In vivo efficacy, biocompatibility and safety were further confirmed acceptable in tumor-bearing mice. The prepared dual sensitization anti-resistant nanoparticles were promising to treat refractory breast cancer with a controllable treatment site and minimal side effects.
Identifiants
pubmed: 36798807
doi: 10.2147/DDDT.S387788
pii: 387788
pmc: PMC9926987
doi:
Substances chimiques
Photosensitizing Agents
0
Paclitaxel
P88XT4IS4D
Porphyrins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-418Informations de copyright
© 2023 Ju et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Biopharm Drug Dispos. 2021 Jan;42(1):12-23
pubmed: 33320969
Cells. 2019 Aug 22;8(9):
pubmed: 31443516
Curr Drug Targets. 2021;22(8):922-946
pubmed: 33461465
Asian Pac J Cancer Prev. 2014;15(24):10659-63
pubmed: 25605156
Crit Rev Biotechnol. 2016 Aug;36(4):716-26
pubmed: 25757878
Am Fam Physician. 2009 Sep 15;80(6):609-16
pubmed: 19817326
Oncotarget. 2017 Jul 6;8(35):59950-59964
pubmed: 28938696
Cancer Lett. 2014 Jun 1;347(2):159-66
pubmed: 24657660
Chem Soc Rev. 2014 Sep 7;43(17):6254-87
pubmed: 24811160
Int J Mol Sci. 2020 May 02;21(9):
pubmed: 32370233
Adv Drug Deliv Rev. 2009 May 20;61(5):381-7
pubmed: 19100797
Molecules. 2020 Jun 06;25(11):
pubmed: 32517278
Int J Pharm. 2021 May 1;600:120532
pubmed: 33781877
Eur J Med Chem. 2018 Mar 10;147:66-76
pubmed: 29421571
Curr Oncol Rep. 2015 Oct;17(10):44
pubmed: 26216506
Cells. 2020 Jul 21;9(7):
pubmed: 32708202
World J Gastroenterol. 2015 May 7;21(17):5158-66
pubmed: 25954089
Pharm Res. 2020 Jan 2;37(2):18
pubmed: 31897768
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Nat Rev Mol Cell Biol. 2008 Jul;9(7):532-42
pubmed: 18568041
Adv Drug Deliv Rev. 2017 Dec 1;122:20-30
pubmed: 28257998
J Pers Med. 2021 Jun 18;11(6):
pubmed: 34207137
Molecules. 2020 Mar 05;25(5):
pubmed: 32151062
Int J Mol Sci. 2021 Apr 28;22(9):
pubmed: 33925129
Expert Opin Drug Deliv. 2020 Nov;17(11):1655-1669
pubmed: 32841584
Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
Int J Pharm. 2017 Jun 30;526(1-2):474-495
pubmed: 28501439
Drugs. 1997;54 Suppl 4:15-21
pubmed: 9361957
Adv Exp Med Biol. 2019;1152:51-64
pubmed: 31456179
Int J Nanomedicine. 2014 May 06;9 Suppl 1:51-63
pubmed: 24872703
Adv Biochem Eng Biotechnol. 1998;62:75-105
pubmed: 9755641
Mol Cell. 2002 Mar;9(3):459-70
pubmed: 11931755
Colloids Surf B Biointerfaces. 2021 Sep;205:111914
pubmed: 34130211
Redox Biol. 2018 Apr;14:316-327
pubmed: 29017115
J Photochem Photobiol B. 2019 Aug;197:111544
pubmed: 31295716
Curr Pharm Des. 2014;20(5):793-807
pubmed: 23688078
Adv Exp Med Biol. 2021;1187:183-204
pubmed: 33983579
Int J Pharm. 2017 Aug 30;529(1-2):506-522
pubmed: 28711640
Cold Spring Harb Protoc. 2016 Nov 1;2016(11):
pubmed: 27803250
J Control Release. 2016 Aug 10;235:337-351
pubmed: 27297779
Adv Exp Med Biol. 2019;1141:13-100
pubmed: 31571164